Influenza in immunocompromised patients: Considerations for therapy

Future Virology

Volumn 6, Issue 7, 2011, Pages 855-868

  Antón, Andrés ^a   Pumarola, Tomàs ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

antiviral; complication; follow up; immunocompromised; immunosuppression; influenza; resistance; therapy; vaccination

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; CORTICOSTEROID; DAS 181; FAVIPIRAVIR; INFLUENZA VACCINE; LANINAMIVIR; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; ZANAMIVIR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; COMBINATION CHEMOTHERAPY; COUGHING; DECISION MAKING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA B; INFLUENZA VIRUS; LUNG INFECTION; MONOTHERAPY; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 79960414814     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.61     Document Type: Review

References (166)

1. Fiore AE, Fry A, Shay D et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Surveill. Summ. 60(1), 1-28 (2011).
2. Lapinsky SE. H1N1 novel influenza A in pregnant and immunocompromised patients. Crit. Care Med. 38(4 Suppl.), E52-E57 (2010).
3. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am. J. Med. 102(3A), 2-9; discussion 25-26 (1997).
4. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J. Antimicrob. Chemother. 65(Suppl. 2), II11-II24 (2010).
5. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9(8), 493-504 (2009).
6. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br. J. Haematol. 143(4), 455-467 (2008).
7. Chemaly RF, Ghosh S, Bodey GP et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 85(5), 278-287 (2006). (Pubitemid 44401460)
8. Lee I, Barton TD. Viral respiratory tract infections in transplant patients: epidemiology, recognition and management. Drugs 67(10), 1411-1427 (2007). (Pubitemid 47026391)
9. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol. Blood Marrow Transplant. 7(Suppl.), 5S-7S (2001). (Pubitemid 33734761)
10. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin. Infect. Dis. 39(9), 1300-1306 (2004). (Pubitemid 39458515)
11. Raboni SM, Nogueira MB, Tsuchiya LR et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 76(1), 142-146 (2003). (Pubitemid 36880830)
12. Espinosa-Aguilar L, Green JS, Forrest GN et al. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences. Biol. Blood Marrow Transplant. 17(4), 566-573 (2011).
13. George B, Ferguson P, Kerridge I, Gilroy N, Gottlieb D, Hertzberg M. The clinical impact of infection with swine flu (H1N109) strain of influenza virus in hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 17(1), 147-153 (2011).
14. Kharfan-Dabaja MA, Velez A, Richards K, Greene JN, Field T, Sandin R. Influenza A/ pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int. J. Hematol. 91(1), 124-127 (2010).
15. Mohty B, Thomas Y, Vukicevic M et al. Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. Bone Marrow Transplant, DOI: 10.1038/bmt.2011.57 (2011) (Epub ahead of print).
16. Rihani R, Hayajneh W, Sultan I et al. Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. DOI: 10.1038/bmt.2010.329 (2011) (Epub ahead of print).
17. Rozovski U, Herishanu Y, Gipstein L, Naparstek E. Fatal H1N1 influenza infection in an allo-SCT recipient. Bone Marrow Transplant. 45(10), 1572-1573 (2010).
18. Redelman-Sidi G, Sepkowitz KA, Huang CK et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J. Infect. 60(4), 257-263 (2010).
19. Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr. Opin. Infect. Dis. 23(4), 365-373 (2010).
20. Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect. Dis. 10(8), 521-526 (2010).
21. Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J. Heart Lung Transplant. 27(3), 282-288 (2008). (Pubitemid 351375106)
22. Keane WR, Helderman JH, Luby J, Gailiunas P, Hull AR, Kokko JP. Epidemic renal transplant rejection associated with influenza A Victoria. Proc. Clin. Dial. Transplant. Forum 8, 232-236 (1978).
23. Khalifah AP, Hachem RR, Chakinala MM et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am. J. Respir. Crit. Care Med. 170(2), 181-187 (2004). (Pubitemid 38925165)
24. Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am. J. Transplant. 2(3), 287-291 (2002). (Pubitemid 36330248)
25. Smud A, Nagel CB, Madsen E et al. Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study. Transplantation 90(12), 1458-1462 (2010).
26. Cohen JP, Macauley C. Susceptibility to influenza A in HIV-positive patients. JAMA 261(2), 245 (1989).
27. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin. Infect. Dis. 31(2), 604-606 (2000). (Pubitemid 32289599)
28. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 98(1), 33-37 (1990). (Pubitemid 20223662)
29. Thurn JR, Henry K. Influenza A pneumonitis in a patient infected with the human immunodeficiency virus (HIV).Chest 95(4), 807-810 (1989). (Pubitemid 19102887)
30. Martinez E, Marcos M, Hoyo-Ulloa I et al. Influenza A H1N1 in HIV-infected adults. HIV Med. 12(4), 236-245 (2011).
31. Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 339(6), 405-406 (1998). (Pubitemid 28363808)
32. Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135(1), 17-26 (2001). (Pubitemid 32619279)
33. Neuzil KM, Coffey CS, Mitchel EF Jr, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J. Acquir. Immune Defic. Syndr. 34(3), 304-307 (2003). (Pubitemid 37377365)
34. Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep. 58(RR-8), 1-52 (2009).
35. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 3(3), 198-202 (1995).
36. Schepetiuk S, Papanaoum K, Qiao M. Spread of influenza A virus infection in hospitalised patients with cancer. Aust. NZ J. Med. 28(4), 475-476 (1998). (Pubitemid 28410780)
37. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119(12), 1198-1208 (1993). (Pubitemid 23361450)
38. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev. Infect. Dis. 11(6), 954-963 (1989).
39. Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302(17), 1872-1879 (2009).
40. WHO. Influenza A(H1N1) 2009 virus: current situation and post-pandemic recommendations. Wkly Epidemiol. Rec. 86(8), 61-66 (2010).
41. Center for International Blood and Marrow Transplant Research (CIBMTR); National Marrow Donor Program (NMDP); European Blood and Marrow Transplant Group (EBMT) et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 44(8), 453-558 (2009).
42. Danzinger-Isakov L, Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant. 9(Suppl. 4), S258-S262 (2009).
43. Ljungman P, Engelhard D, De La Camara R et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 35(8), 737-746 (2005). (Pubitemid 40613780)
44. Mofenson LM, Brady MT, Danner SP et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm. Rep. 58(RR-11), 1-166 (2009).
45. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 11(1), 1-5 (1993). (Pubitemid 23086839)
46. Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol. Dial. Transplant. 13(1), 160-164 (1998). (Pubitemid 28033597)
47. Keshtkar-Jahromi M, Argani H, Rahnavardi M et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am. J. Nephrol. 28(4), 654-660 (2008). (Pubitemid 351832453)
48. Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42(4), 376-379 (1986). (Pubitemid 16005764)
49. Banic S, Koren S, Tomazic J et al. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. Acta Virol. 45(1), 39-44 (2001). (Pubitemid 32448416)
50. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin. Infect. Dis. 28(3), 541-547 (1999). (Pubitemid 29242531)
51. Gunthard HF, Wong JK, Spina CA et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis 181(2), 522-531 (2000). (Pubitemid 30131819)
52. Ho DD. HIV-1 viraemia and influenza. Lancet 339(8808), 1549 (1992).
53. Kolber MA, Gabr AH, De La Rosa A et al. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS 16(4), 537-542 (2002). (Pubitemid 34218848)
54. O'Brien WA, Grovit-Ferbas K, Namazi A et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86(3), 1082-1089 (1995).
55. + individuals. Clin. Exp. Immunol. 104(2), 203-207 (1996). (Pubitemid 26139775)
56. Staprans SI, Hamilton BL, Follansbee SE et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182(6), 1727-1737 (1995).
57. Tasker SA, O'Brien WA, Treanor JJ et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 16(9-10), 1039-1042 (1998). (Pubitemid 28276020)
58. Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA, Gentry S. Association of renal allograft rejection with virus infections. Am. J. Med. 56(3), 280-289 (1974).
59. Blumberg EA, Fitzpatrick J, Stutman PC, Hayden FG, Brozena SC. Safety of influenza vaccine in heart transplant recipients. J. Heart Lung Transplant. 17(11), 1075-1080 (1998). (Pubitemid 28547275)
60. Gabriel R, Selwyn S, Brown D et al. Virus infections and acute renal transplant rejection. Nephron 16(4), 282-286 (1976).
61. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131(6), 430-433 (1999). (Pubitemid 29444433)
62. Ison MG, De Jong MD, Gilligan KJ et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J. Infect. Dis. 201(11), 1654-1662 (2010).
63. Bermejo-Martin JF, Martin-Loeches I, Rello J et al. Host adaptive immunity deficiency in severe pandemic influenza. Crit. Care 14(5), R167 (2010).
64. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 67(9), 5585-5594 (1993). (Pubitemid 23241395)
65. De Clercq E. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5(12), 1015-1025 (2006). (Pubitemid 44835128)
66. De Clercq E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2(9), 704-720 (2004). (Pubitemid 39206268)
67. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353(13), 1363-1373 (2005). (Pubitemid 41362704)
68. Mckimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47(7), 2264-2272 (2003). (Pubitemid 36753582)
69. CDC. Update: influenza activity - United States, September 30, 2007-February 9, 2008. MMWR Morb. Mortal. Wkly Rep. 57(7), 179-183 (2008).
70. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. 13(5), 8026 (2008).
71. Duwe SC, Wedde M, Birkner P, Schweiger B. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany. Antiviral Res. 89(1), 115-118 (2011).
72. Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N, Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Res. 73(2), 112-117 (2007). (Pubitemid 46135769)
73. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175-1181 (2005). (Pubitemid 41393595)
74. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295(8), 891-894 (2006).
75. CDC. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly Rep. 58(16), 433-435 (2009).
76. Cheung CL, Rayner JM, Smith GJ et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis 193(12), 1626-1629 (2006). (Pubitemid 43839465)
77. He G, Qiao J, Dong C, He C, Zhao L, Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res. 77(1), 72-76 (2008).
78. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73(3), 228-231 (2007).
79. Deyde VM, Xu X, Bright RA et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis 196(2), 249-257 (2007). (Pubitemid 47047464)
80. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18(Suppl. B), 19-29 (1986). (Pubitemid 17199048)
81. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin. Infect. Dis. 34(5), E23-E25 (2002).
82. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53(1), 47-61 (2002). (Pubitemid 33001554)
83. Monto AS, Mckimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50(7), 2395-2402 (2006). (Pubitemid 43993177)
84. Mungall BA, Xu X, Klimov A. Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays. Avian Dis. 47(3 Suppl.), 1141-1144 (2003). (Pubitemid 37143902)
85. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10(1), 45-55 (2000). (Pubitemid 30103133)
86. Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41(2), 742-750 (2003). (Pubitemid 36184190)
87. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48(Suppl. 1), S3-S13 (2009).
88. Deyde VM, Okomo-Adhiambo M, Sheu TG et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81(1), 16-24 (2009).
89. Ghedin E, Fitch A, Boyne A et al. Mixed infection and the genesis of influenza virus diversity. J. Virol. 83(17), 8832-8841 (2009).
90. Ghedin E, Laplante J, Depasse J et al. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J. Infect. Dis 203(2), 168-174 (2011).
91. Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285(6), 748-754 (2001). (Pubitemid 32167233)
92. Gupta YK, Padhy BM. Issues in pharmacotherapy of 2009 H1N1 influenza infection. J. Postgrad. Med. 56(4), 321-327 (2010).
93. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 163(14), 1667-1672 (2003). (Pubitemid 36898954)
94. Machado CM, Boas LS, Mendes AV et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant. 34(2), 111-114 (2004). (Pubitemid 39077100)
95. Vu D, Peck AJ, Nichols WG et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin. Infect. Dis. 45(2), 187-193 (2007). (Pubitemid 47041009)
96. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J. Infect. Dis 194(Suppl. 2), S133-S138 (2006). (Pubitemid 44630957)
97. Khanna N, Steffen I, Studt JD et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 11(2), 100-105 (2009).
98. Chemaly RF, Torres HA, Aguilera EA et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin. Infect. Dis. 44(7), 964-967 (2007). (Pubitemid 46452062)
99. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 78(1), 91-102 (2008)
100. Nguyen JT, Hoopes JD, Smee DF et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 53(10), 4115-4126 (2009).
101. Shay DK, Ridenhour BJ. Can we 'hedge' against the development of antiviral resistance among pandemic influenza viruses? PLoS Med. 6(6), E1000103 (2009).
102. Le QM, Wertheim HF, Tran ND, Van Doorn HR, Nguyen TH, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N. Engl. J. Med. 362(1), 86-87 (2010).
103. Graitcer SB, Gubareva L, Kamimoto L et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg. Infect. Dis. 17(2), 255-257 (2011).
104. Ellis J, Galiano M, Pebody R et al. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11. Euro. Surveill. 16(1), PII/19774; author reply PII/19773 (2011).
105. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N. Engl. J. Med. 361(23), 2296-2297 (2009).
106. Anton A, Lopez-Iglesias AA, Tortola T et al. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn. Microbiol. Infect. Dis. 68(3), 214-219 (2010).
107. CDC. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb. Mortal. Wkly Rep. 58(32), 893-896 (2009).
108. CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb. Mortal. Wkly Rep. 58(35), 969-972 (2009).
109. CDC. Update: influenza activity - United States, 2009-2010 season. MMWR Morb. Mortal. Wkly Rep. 59(29), 901-908 (2010).
110. Englund JA, Champlin RE, Wyde PR et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin. Infect. Dis. 26(6), 1418-1424 (1998). (Pubitemid 28270175)
111. Gaur AH, Bagga B, Barman S et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N. Engl. J. Med. 362(1), 88-89 (2010).
112. Lee N, Chan PK, Hui DS et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J. Infect. Dis 200(4), 492-500 (2009).
113. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect. Control Hosp. Epidemiol. 28(9), 1071-1076 (2007). (Pubitemid 47345268)
114. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283(8), 1016-1024 (2000). (Pubitemid 30112215)
115. Ison MG, Gnann JW Jr, Nagy-Agren S et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 8(3), 183-190 (2003). (Pubitemid 36960891)
116. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 352(9144), 1877-1881 (1998).
117. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20(2), 127-133 (2001). (Pubitemid 32151932)
118. Boivin G, Coulombe Z, Wat C. Quantification of the influenza virus load by real-time polymerase chain reaction in nasopharyngeal swabs of patients treated with oseltamivir. J. Infect. Dis 188(4), 578-580 (2003). (Pubitemid 37011811)
119. Carrat F, Vergu E, Ferguson NM et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am. J. Epidemiol. 167(7), 775-785 (2008). (Pubitemid 351451744)
120. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J. Infect. Dis 199(10), 1435-1441 (2009).
121. Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282(13), 1240-1246 (1999). (Pubitemid 29468495)
122. Ling LM, Chow AL, Lye DC et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin. Infect. Dis. 50(7), 963-969 (2010).
123. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41(1), 13-19 (2008). (Pubitemid 350298978)
124. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 47(1), 1-17 (2000). (Pubitemid 30621392)
125. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103(1-2), 199-203 (2004). (Pubitemid 38649080)
126. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis 178(5), 1257-1262 (1998).
127. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis 193(6), 760-764 (2006).
128. Storch GA. Rapid diagnostic tests for influenza. Curr. Opin. Pediatr. 15(1), 77-84 (2003). (Pubitemid 36132621)
129. Grijalva CG, Poehling KA, Edwards KM et al. Accuracy and interpretation of rapid influenza tests in children. Pediatrics 119(1), E6-E11 (2007). (Pubitemid 46397799)
130. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J. Clin. Virol. 39(2), 132-135 (2007). (Pubitemid 46777422)
131. Steininger C, Redlberger M, Graninger W, Kundi M, Popow-Kraupp T. Near-patient assays for diagnosis of influenza virus infection in adult patients. Clin. Microbiol. Infect. 15(3), 267-273 (2009).
132. Uyeki TM, Prasad R, Vukotich C et al. Low sensitivity of rapid diagnostic test for influenza. Clin. Infect. Dis. 48(9), E89-E92 (2009).
133. Moscona A. Medical management of influenza infection. Annu. Rev. Med. 59, 397-413 (2008). (Pubitemid 351287945)
134. Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51(1), 123-129 (2003). (Pubitemid 36163836)
135. Lee N, Chan PK, Choi KW et al. Factors associated with early hospital discharge of adult influenza patients. Antivir. Ther. 12(4), 501-508 (2007). (Pubitemid 47041148)
136. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358(3), 261-273 (2008).
137. Chowell G, Bertozzi SM, Colchero MA et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N. Engl. J. Med. 361(7), 674-679 (2009).
138. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N. Engl. J. Med. 361(20), 1935-1944 (2009).
139. Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374(9688), 451-458 (2009).
140. Kandun IN, Tresnaningsih E, Purba WH et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 372(9640), 744-749 (2008).
141. Mcgeer A, Green KA, Plevneshi A et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 45(12), 1568-1575 (2007). (Pubitemid 351411840)
142. Perez-Padilla R, De La Rosa-Zamboni D, Ponce De Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med. 361(7), 680-689 (2009).
143. Adisasmito W, Chan PK, Lee N et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J. Infect. Dis 202(8), 1154-1160 (2010).
144. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43(12), 1555-1561 (2006). (Pubitemid 44901897)
145. Ison MG. Respiratory viral infections in transplant recipients. Antivir. Ther. 12(4 Pt B), 627-638 (2007). (Pubitemid 47235505)
146. Hanshaoworakul W, Simmerman JM, Narueponjirakul U et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 4(6), E6051 (2009).
147. Lee N, Cockram CS, Chan PK, Hui DS, Choi KW, Sung JJ. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin. Infect. Dis. 46(8), 1323-1324 (2008). (Pubitemid 351589924)
148. Allen UD, Aoki FY, Stiver HG. The use of antiviral drugs for influenza: recommended guidelines for practitioners. Can. J. Infect. Dis. Med. Microbiol. 17(5), 273-284 (2006). (Pubitemid 44898665)
149. Taylor WR, Thinh BN, Anh GT et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 3(10), E3410 (2008).
150. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr. Pharm. Des. 13(34), 3531-3542 (2007). (Pubitemid 350238942)
151. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43(7), 1616-1620 (1999). (Pubitemid 29331237)
152. Macdonald SJ, Watson KG, Cameron R et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob. Agents Chemother. 48(12), 4542-4549 (2004). (Pubitemid 39577651)
153. Furuta Y, Takahashi K, Fukuda Y et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46(4), 977-981 (2002). (Pubitemid 34260339)
154. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49(3), 981-986 (2005). (Pubitemid 40327713)
155. Belser JA, Lu X, Szretter KJ et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis 196(10), 1493-1499 (2007). (Pubitemid 351411986)
156. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50(4), 1470-1479 (2006).
157. Kidd IM, Down J, Nastouli E et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 374(9694), 1036 (2009).
158. Englund J, Zerr D, Heath J. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb. Mortal. Wkly Rep. 58(32), 893-896 (2009).
159. Dulek DE, Williams JV, Creech CB et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin. Infect. Dis. 50(11), 1493-1496 (2010).
160. Harter G, Zimmermann O, Maier L et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin. Infect. Dis. 50(9), 1249-1251 (2010).
161. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49(11), 4515-4520 (2005). (Pubitemid 41552580)
162. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 54(11), 4568-4574 (2010).
163. Hollister AS, Sheridan WP. The emergency use authorization of peramivir IV: a view from the manufacturer. Clin. Pharmacol. Ther. 89(2), 172-174 (2011).
164. Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83(1), 90-93 (2009).
165. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/ H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 74(2), 159-162 (2007). (Pubitemid 46436166)
166. Renaud C, Pergam SA, Polyak C et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl. Infect. Dis. 12(6), 513-517 (2010).